Abstract
G protein-coupled receptors (GPCRs) are considered to represent the most promising drug targets; it has been repeatedly said that a large fraction of the currently marketed drugs elicit their actions by binding to GPCRs (with cited numbers varying from 30-50%). Closer scrutiny, however, shows that only a modest fraction of (∼60) GPCRs are, in fact, exploited as drug targets, only ∼20 of which are peptide-binding receptors. The vast majority of receptors in the humane genome have not yet been explored as sites of action for drugs. Given the drugability of this receptor class, it appears that opportunities for drug discovery abound. In addition, GPCRs provide for binding sites other than the ligand binding sites (referred to as the “orthosteric site”). These additional sites include (i) binding sites for ligands (referred to as “allosteric ligands”) that modulate the affinity and efficacy of orthosteric ligands, (ii) the interaction surface that recruits G proteins and arrestins, (iii) the interaction sites of additional proteins (GIPs, GPCR interacting proteins that regulate G protein signaling or give rise to G protein-independent signals). These sites can also be targeted by peptides. Combinatorial and natural peptide libraries are therefore likely to play a major role in identifying new GPCR ligands at each of these sites. In particular the diverse natural peptide libraries such as the venom peptides from marine cone-snails and plant cyclotides have been established as a rich source of drug leads. High-throughput screening and combinatorial chemistry approaches allow for progressing from these starting points to potential drug candidates. This will be illustrated by focusing on the ligand-based drug design of oxytocin (OT) and vasopressin (AVP) receptor ligands using natural peptide leads as starting points.
Keywords: GPCR, drug, ligand-based design, peptide, cyclotide, conotoxin, oxytocin, vasopressin
Current Pharmaceutical Design
Title: Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Volume: 16 Issue: 28
Author(s): Christian W. Gruber, Markus Muttenthaler and Michael Freissmuth
Affiliation:
Keywords: GPCR, drug, ligand-based design, peptide, cyclotide, conotoxin, oxytocin, vasopressin
Abstract: G protein-coupled receptors (GPCRs) are considered to represent the most promising drug targets; it has been repeatedly said that a large fraction of the currently marketed drugs elicit their actions by binding to GPCRs (with cited numbers varying from 30-50%). Closer scrutiny, however, shows that only a modest fraction of (∼60) GPCRs are, in fact, exploited as drug targets, only ∼20 of which are peptide-binding receptors. The vast majority of receptors in the humane genome have not yet been explored as sites of action for drugs. Given the drugability of this receptor class, it appears that opportunities for drug discovery abound. In addition, GPCRs provide for binding sites other than the ligand binding sites (referred to as the “orthosteric site”). These additional sites include (i) binding sites for ligands (referred to as “allosteric ligands”) that modulate the affinity and efficacy of orthosteric ligands, (ii) the interaction surface that recruits G proteins and arrestins, (iii) the interaction sites of additional proteins (GIPs, GPCR interacting proteins that regulate G protein signaling or give rise to G protein-independent signals). These sites can also be targeted by peptides. Combinatorial and natural peptide libraries are therefore likely to play a major role in identifying new GPCR ligands at each of these sites. In particular the diverse natural peptide libraries such as the venom peptides from marine cone-snails and plant cyclotides have been established as a rich source of drug leads. High-throughput screening and combinatorial chemistry approaches allow for progressing from these starting points to potential drug candidates. This will be illustrated by focusing on the ligand-based drug design of oxytocin (OT) and vasopressin (AVP) receptor ligands using natural peptide leads as starting points.
Export Options
About this article
Cite this article as:
W. Gruber Christian, Muttenthaler Markus and Freissmuth Michael, Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors, Current Pharmaceutical Design 2010; 16 (28) . https://dx.doi.org/10.2174/138161210793292474
DOI https://dx.doi.org/10.2174/138161210793292474 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Cures of Vascular Disease - The State
Current Vascular Pharmacology Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Is Combination Therapy of Atosiban and Nifedipine More Effective in Preterm Labor than Each Drug Alone? A Prospective Study
Current Women`s Health Reviews Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry α-Fibrinogenases
Current Drug Targets - Cardiovascular & Hematological Disorders Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery An Efficient Multiple Kernel Support Vector Regression Model for Assessing Dry Weight of Hemodialysis Patients
Current Bioinformatics Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Continuous Renal Replacement Therapy in Children Post-Hematopoietic Stem Cell Transplantation: The Present and the Future
Current Stem Cell Research & Therapy Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry The Pathophysiology of CTGs and Types of Intrapartum Hypoxia
Current Women`s Health Reviews Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Chest Pain in Children
Current Pediatric Reviews